^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mesothelioma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Malignant Peritoneal Mesothelioma…SUBSEQUENT SYSTEMIC THERAPY…Preferred Atezolizumab/bevacizumab